Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis.
about
PI3K/AKT/mTOR Pathway in AngiogenesisKRIT1, a gene mutated in cerebral cavernous malformation, encodes a microtubule-associated protein.Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptorsmiR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis.RAS oncogenes: weaving a tumorigenic webMutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathwayThe transcription factor Net regulates the angiogenic switchNf1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor of farnesyl protein transferaseAngiogenic heterogeneity in head and neck squamous cell carcinoma: biological and therapeutic implicationsRole of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab: A retrospective analysis.YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical modelsAngiogenesis inhibitors: current strategies and future prospects.Activated STAT3 is a mediator and biomarker of VEGF endothelial activationPhospholipase D signaling pathways and phosphatidic acid as therapeutic targets in cancerDifferential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimersSpontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib.RBMS3 at 3p24 inhibits nasopharyngeal carcinoma development via inhibiting cell proliferation, angiogenesis, and inducing apoptosisInterruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment.Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapyRhoC GTPase overexpression modulates induction of angiogenic factors in breast cells.DDAH1 deficiency attenuates endothelial cell cycle progression and angiogenesis.Noninvasive MRI of endothelial cell response to human breast cancer cells.Induction of Ras by SAF-1/MAZ through a feed-forward loop promotes angiogenesis in breast cancer.Cannabinoids and cancer: pros and cons of an antitumour strategy.An in vivo function for the transforming Myc protein: elicitation of the angiogenic phenotype.Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view.Collateral expression of proangiogenic and tumorigenic properties in intestinal epithelial cell variants selected for resistance to anoikisTumor angiogenesis as a target for dietary cancer preventionTargeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia.Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis.Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomasInducible nitric oxide synthase expression in human colorectal cancer: correlation with tumor angiogenesis.Development of keratoacanthomas and squamous cell carcinomas in transgenic rabbits with targeted expression of EJras oncogene in epidermis.Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGFR-1 and VEGFR-2 in vivo.Inhibition of MAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells.Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways.Suppression of human breast tumors in NOD/SCID mice by CD44 shRNA gene therapy combined with doxorubicin treatmentFarnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level.Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells.Atherosclerosis and vascular aging as modifiers of tumor progression, angiogenesis, and responsiveness to therapy.
P2860
Q21129332-D0C749F2-7C47-4D1A-BEDB-98130E8CBC82Q24533596-7AE041ED-CB3A-42B7-93EB-AAC371800298Q24554356-C76A48BB-CAC6-4015-84C3-1EF81981F6D8Q24613599-B8554347-0741-4E87-A2E7-C83DD40CA46DQ28250360-2366A3FE-B86A-4079-A674-0DB2A3890A37Q28365260-924678C5-3318-4C10-90A3-3ED63C1F2532Q28504967-1DB3E31D-2826-4BF3-9CC5-167976D04E05Q28588037-876DD508-2E53-4791-902A-1E9F3BE9BD51Q33320268-8586EF4E-F801-44C1-BCBE-E6EA1108D4B1Q33599123-AEA29135-40A7-4B13-A7A1-A7DEBDA8D424Q34030791-5944992A-411B-48F6-9680-052CB2659920Q34056376-ADB5E08A-6000-4F24-9C67-15BABF0AFD4EQ34099797-EB103A7D-0E7F-4A9D-944F-3E8922D5D39FQ34268347-4D8159C3-E9EC-4A77-A9F7-5F1A56524369Q34274718-160DBA40-21C2-4193-909B-EB0CACBBD55EQ34356841-B63D60F9-0DD1-4E24-B5C2-C981E6E68780Q34408248-287B8E2E-B90A-4D67-A255-E071211640BAQ34573041-DE164F94-4411-49F6-A850-8757D5925F1FQ34743875-0375E0A6-1B78-43F8-ACAA-923DBBC4D064Q34785853-549F1AE3-47B3-4C1B-94CF-A3DCE850EAE6Q35048434-B20F2871-821A-4BDE-9317-7A197BCE8C7DQ35052184-73214543-0BE9-468C-B395-2CE231A66828Q35084925-3543A467-1264-4275-A41B-9AE73DBB3095Q35100892-59E46F49-0050-4515-BC95-1A96E8032BE5Q35128710-23CE662A-947B-418D-ADEA-4E090C70AEF1Q35223622-D7572078-F73D-4E62-93E7-78AD0E0A8765Q35250097-363D2A99-F0ED-419B-91FF-9071BE7C7050Q35250910-DF6ADA92-D2CA-49A7-8545-B684665E87BDQ35751013-E0B5BFC6-9DE6-4166-8F19-55297E044F58Q35782469-EEC6BA77-1079-4AF1-BB9D-BEBB6A0DB69BQ35789079-161A3FC9-4E2E-43CA-A27D-18CD6B5DAB7EQ35791288-9592968F-ADB3-4C22-BC49-2F21B80686FFQ35793293-5AA81BB6-4F68-40C2-819B-3E41BC2DA8B9Q35809985-BE3FCED8-1AF4-4627-8ABD-036B900A5C94Q35829637-067D73D4-A6CC-4D53-BBE7-D0F3504BFDB8Q35964906-4FD77C60-64AC-4C1F-9D6E-0D1D350561BAQ35979751-0C26D0B5-5D3D-4A3D-9D1E-54879C35B116Q35990656-C2702B82-BA97-41D5-A2B5-2ED9AC51B0C2Q36006469-333C4F4C-5260-4FF9-810B-F2555B68AC19Q36007486-9B29A5D5-3558-4FCF-8DD3-E1FDB1F7D27B
P2860
Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh-hant
name
Mutant ras oncogenes upregulat ...... ibition of tumor angiogenesis.
@en
Mutant ras oncogenes upregulat ...... ibition of tumor angiogenesis.
@nl
type
label
Mutant ras oncogenes upregulat ...... ibition of tumor angiogenesis.
@en
Mutant ras oncogenes upregulat ...... ibition of tumor angiogenesis.
@nl
prefLabel
Mutant ras oncogenes upregulat ...... ibition of tumor angiogenesis.
@en
Mutant ras oncogenes upregulat ...... ibition of tumor angiogenesis.
@nl
P2093
P1433
P1476
Mutant ras oncogenes upregulat ...... hibition of tumor angiogenesis
@en
P2093
Mitsuhashi Y
Sasazuki T
Shirasawa S
P304
P407
P577
1995-10-01T00:00:00Z